Normal view MARC view ISBD view

A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. [Review]

MedStar author(s):

Citation: European Journal of Surgical Oncology. 42(8):1123-31, 2016 AugPMID: 27160355Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | *Cytoreduction Surgical Procedures/mt [Methods] | *Hyperthermia, Induced/mt [Methods] | *Peritoneal Neoplasms/th [Therapy] | *Stomach Neoplasms/su [Surgery] | Cisplatin/ad [Administration & Dosage] | Drug Combinations | Humans | Infusions, Parenteral | Multivariate Analysis | Neoadjuvant Therapy | Oxonic Acid/ad [Administration & Dosage] | Peritoneal Neoplasms/sc [Secondary] | Peritoneum/su [Surgery] | Stomach Neoplasms/pa [Pathology] | Taxoids/ad [Administration & Dosage] | Tegafur/ad [Administration & Dosage]Year: 2016 Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:2002-2007ISSN:

0748-7983

Name of journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyAbstract: Copyright (c) 2016 Elsevier Ltd. All rights reserved.Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed. Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC. All authors: Batlett D, Canbay E, Coccolini F, Deraco M, Elias D, Glehen O, Gonzaletz-Moreno S, Ishibashi H, Li Y, Mahtem H, Mizumoto A, Moran B, Morris D, Piso P, Sugarbaker PH, Verwaal V, Yonemura YFiscal year: FY2017Digital Object Identifier:

https://dx.doi.org/10.1016/j.ejso.2016.03.016

Date added to catalog: 2017-04-11

Holdings ( 1 )
Title notes ( 4 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	27160355	Available		27160355

Available online from MWHC library: 1995 - present, Available in print through MWHC library:2002-2007

Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed. Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC.

English